招商证券(香港)：维持石药集团买入评级，目标价13.93港元。 ...

Core Viewpoint - Zhejiang Mining Co., Ltd. (300837.SZ) is experiencing a significant decline in stock price, closing at 45.10 yuan with a drop of 13.14%, resulting in a total market capitalization of 4.51 billion yuan. The company is expected to benefit from its business structure and operational model upgrades, along with the acquisition of overseas lead-silver mines, which may enhance future performance [1]. Group 1 - The research report from China Merchants Securities highlights the positive outlook for Zhejiang Mining's development in sand and gravel mining, metal mining, and resource recycling [1]. - The report anticipates that the acquisition of overseas lead-silver mines will contribute to the company's earnings growth in the future [1]. - The company is assigned a price-to-earnings (PE) ratio forecast of 65.4, 53.9, and 48.1 for the years 2025, 2026, and 2027 respectively, with an initial investment rating of "Buy" [1].

Group 1 - Company KANGXIN Communication (688653.SH) forecasts a revenue of approximately 683.5 million yuan for 2025, representing a year-on-year increase of about 30.74% [1] - The company expects a net loss attributable to shareholders of approximately -43.5 million yuan for 2025, which is a reduction in loss of about 42.86% compared to the previous year [1] - For 2024, KANGXIN Communication reported a revenue of 523 million yuan, a year-on-year growth of 25.98%, but a net loss of -76.1 million yuan compared to a profit of 9.9 million yuan in the previous year [1] Group 2 - KANGXIN Communication was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on November 17, 2023, with an initial public offering of 63.68 million shares at a price of 10.50 yuan per share [2] - The total funds raised by KANGXIN Communication amounted to 668.64 million yuan, with a net amount of 599.67 million yuan, which is 18.20 million yuan less than originally planned [3] - The company plans to use the raised funds for the development and industrialization of next-generation Wi-Fi RF front-end chips, IoT wireless RF front-end chips, and the establishment of a technology R&D center [3]

Core Viewpoint - The report from China Merchants Securities International highlights a historic deal between CSPC Pharmaceutical Group (01093) and AstraZeneca (AZN.US), expressing optimism about the transaction but indicating the need for further details on the long-acting GLP-1 global development from either CSPC or AstraZeneca [1] Group 1: Transaction Details - CSPC's key clinical candidate in collaboration with AstraZeneca is SYH2082, a long-acting GLP-1R/GIPR dual agonist, which has entered Phase I clinical trials [1] - The report notes that there is limited understanding of the long-acting GLP-1 platform, as SYH2082 has just initiated Phase I research in China [1] Group 2: Investment Outlook - The firm maintains a "neutral" rating, citing short-term fundamental concerns despite a long-term positive outlook on "Chinese innovative drugs entering the global pipeline" [1] - Investors are advised to carefully examine the asset valuation factors that may have already been priced in by the market prior to the business development announcement [1] Group 3: Market Competition - The entry of siRNA into the obesity maintenance market poses a significant threat to all peptide-based solutions [1] - The report emphasizes that siRNA drugs targeting weight loss and muscle preservation may ultimately pressure peptide-based obesity therapies, with a focus on the progress of Arrowhead and Wave siRNA assets [1] - Investors are encouraged to monitor the future impact of siINHBE and siALK7 targets on the weight maintenance market [1]

Core Viewpoint - The report from China Merchants Securities International highlights a historic deal between CSPC Pharmaceutical Group (01093) and AstraZeneca (AZN.US), expressing optimism about the transaction but indicating the need for further details on the long-acting GLP-1 global development from either CSPC or AstraZeneca [1] Group 1: Transaction Details - CSPC's key clinical candidate in collaboration with AstraZeneca is SYH2082, a long-acting GLP-1R/GIPR dual agonist, which has entered Phase I clinical trials [1] - The report notes that there is limited understanding of the long-acting GLP-1 platform, as SYH2082 has just initiated Phase I research in China [1] Group 2: Investment Outlook - The firm maintains a "neutral" rating, citing short-term fundamental concerns despite a long-term positive outlook on "Chinese innovative drugs entering the global pipeline" [1] - Investors are advised to carefully examine the asset valuation factors that may have already been priced in by the market prior to the business development announcement [1] Group 3: Market Competition - The entry of siRNA into the obesity maintenance market poses a significant threat to all peptide-based solutions [1] - The report emphasizes that siRNA drugs targeting weight loss and muscle preservation may ultimately pressure peptide-based obesity therapies, with a focus on the progress of Arrowhead and Wave siRNA assets [1] - Investors are encouraged to monitor the future impact of siINHBE and siALK7 targets on the weight maintenance market [1]

Core Viewpoint - The report from China Merchants Securities International predicts that the humanoid robot industry in China will experience significant growth by 2026 due to advancements in AI model capabilities, hardware technology maturity, cost reductions, and accelerated application scenarios, along with a surge in orders in the fourth quarter [1] Group 1: Recommended Companies - Recommended humanoid robot manufacturers include UBTECH Robotics (09880), Yujin Robot (02432), and Geek+ (02590) [1] - Cross-industry collaborative companies recommended are Tesla (TSLA.US) and Xpeng Motors (09868) [1] - Ecological companies to watch include Xiaomi Group (01810) and Midea Group (00300) [1] Group 2: Supply Chain Insights - The supply chain outlook is positive, focusing on technology convergence, with a favorable view on Minth Group (00425) in the Hong Kong stock market [1] - Companies expanding from intelligent driving to robotics, such as Hesai Technology (02525) and Horizon Robotics (09660), are also highlighted as promising [1] Group 3: Industry Trends - The humanoid robot industry in China is characterized by rapid incremental advancements and a full-chain explosion, particularly with the trend of large-scale production by overseas leaders by the end of the year [1] - Catalysts for growth include the release of Tesla's V3 and the listing of Yushu Technology, along with a significant number of new robot companies expected to go public in the Hong Kong market this year [1]

Market Outlook - The market is expected to remain volatile in February, with indices likely to perform better post-holiday compared to pre-holiday levels [1][2] - The lack of clear catalysts before the Spring Festival is anticipated to reduce market activity, while policy catalysts are expected to accelerate after the holiday due to the upcoming Two Sessions [2] Fundamental Analysis - The period of January to February is characterized as a data vacuum, with market focus on marginal improvements in performance driven by industrial changes [2] - Key sectors include cyclical price increases, particularly in semiconductors and AI-related products, which are expected to maintain a positive trend [2][5] Liquidity and Capital Supply - February is projected to see continued net inflows of incremental capital, with foreign capital expected to flow in before the holiday and financing likely to rebound afterward [4] - The central bank is expected to maintain a stable liquidity environment through targeted measures, despite some liquidity tightening from government bond issuances [4] Industry Recommendations - The report suggests focusing on cyclical and technology sectors, with increased attention on discretionary consumption as the Spring Festival approaches [3][6] - Recommended sectors include electronics (semiconductors), media (advertising, gaming, film), machinery (automation, engineering), power equipment (batteries, grid equipment, photovoltaic), basic chemicals, and social services [3][6] Performance Trends - In January, high-performing sectors included certain resource products, public utilities, and information technology, with notable price increases in industrial metals and chemicals [6] - The report highlights a recovery in profitability for certain sectors, particularly in resource products and TMT (Technology, Media, Telecommunications) driven by AI [5][6]

转自：中国证券报·中证网 中证报中证网讯（记者 齐金钊）日前，2025招商证券"招财杯"ETF实盘大赛落下帷幕。本届大赛于2025 年4月28日正式启幕，招商证券携手易方达基金、招商基金、博时基金、摩根基金、银华基金、汇添富 基金、华夏基金、国泰基金、广发基金、鹏华基金十大基金公司（排名不分先后），共同为投资者打造 一个集学习、交流、成长于一体的投教平台。据统计，本届大赛浏览量超880万人次，活跃度较上届大 赛增长超六成，实现显著增长。 据悉，为了让更多投资者领略ETF投资的魅力，自2023年起，招商证券已连续三年举办"招财杯"ETF实 盘大赛，累计吸引近27万名选手报名参赛，投教及赛事相关内容累计触达投资者超过千万人次，逐步构 建起良性循环的ETF投资生态圈。 数据显示，2025年"招财杯"ETF实盘大赛报名人数近八万。从重仓板块来看，排名居前的选手们主要在 宽基ETF与生物医药、通信设备、半导体芯片等行业主题ETF中灵活轮动，体现了对市场热点的关注与 配置调整。 招商证券表示，大赛的圆满收官，既是过往成果的总结，更是投资者ETF投资实践的新起点。 招商证 券将始终秉承"用心服务客户，专业创造价值"的核心理 ...

Core Viewpoint - The report from招商证券 indicates a significant decline in overall demand for liquor, particularly in the white liquor market, with double-digit decreases expected, aligning with prior forecasts [1] Group 1: Market Demand - Recent surveys conducted by招商证券 in regions such as Henan, Anhui, and Sichuan reveal that total demand for white liquor is still declining [1] - The decline in demand is primarily observed in business banquets, which are now dominated by smaller gatherings, while mid-to-high-end dining remains sluggish [1] - There is a partial recovery in gift-giving demand, indicating some shifts in consumer behavior [1] Group 2: Brand Performance - There is a noticeable differentiation among brands, with茅台 showing strong sales performance and benefiting from pre-holiday stocking demands [1] - Other brands are facing pressure and challenges in maintaining their market positions [1]

Core Viewpoint - The supply-demand relationship for Moutai prices remains unchanged in the short term, with low inventory among distributors and tight supply supporting a potential price increase [1] Short-term Analysis - Moutai's allocation quotas are nearly fulfilled before the year-end, leading to low distributor inventory levels [1] - Demand is expected to grow year-on-year at a double-digit rate, providing support for price increases [1] Long-term Perspective - Currently, the industry is at the bottom of the economic cycle, facing multiple negative constraints such as economic pressure and alcohol bans, which limit demand [1] - The solid bottom of supply-demand balance may lead to the removal of constraints in the future, creating upward price momentum and driving valuation and performance improvements [1]